Jyoti Resins and Adhesives Ltd
JYOTIRESJyoti Resins and Adhesives Ltd is cheap for a reason. The P/E sits at the 14th percentile of its own range, and the quarters are still getting worse.
The sharpest disagreement: annual EPS moved +10.1% against a −33.3% price move — the market has not yet caught up with the delivery.
The price is in a downtrend (24 weeks in) while the P/E sits at the 14th percentile of its own 10-year range. Underneath, the last four quarters read deteriorating — profit −21.1% year on year, and 23% of the last 3 years' profit arrived as cash. What settles it: whether the price catches up with earnings that have already moved.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Jyoti Resins and Adhesives Ltd trades at ₹831, in a downtrend and 24 weeks into that stage. That is −28.4% against its own 200-day average. It sits at 0% of a 52-week range of ₹831 to ₹1,453. On relative strength it is currently behind the NIFTY 500 on a trailing-13-week view (30 weeks and counting).
Today the stock is in a downtrend — week 24 of stage 4, confirmed. At ₹831 it trades −28.4% versus its 200-day average and sits at 0% of its 52-week range (₹831–₹1,453).
Against the market, two honest reads. Cumulative: over the last 10.0 years the stock moved +2,603% while the NIFTY 500 moved +260% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (30 weeks and counting; last ahead the week of 2025-08-08) — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Jyoti Resins and Adhesives Ltd trades at 14.3× P/E, near the bottom of its own range — cheaper only 14% of the time. Its long-run median P/E is 24.9×, measured across 10.0 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 14.3× is near the bottom of its own range — cheaper only 14% of the time, against a long-run median of 24.9× measured over 10.0 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year annual EPS moved +10.1% against a −33.3% price move — earnings outran the price, pushing the multiple DOWN its own range.
The price move, decomposed: over 5y, of the +38.7%/yr price move, ~+44.8%/yr came from earnings growth and ~−6.1 pp from the multiple (compressing); over 10y, of the +39.1%/yr price move, ~+59.6%/yr came from earnings growth and ~−20.5 pp from the multiple (compressing). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is low against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: Topping out Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Jyoti Resins and Adhesives Ltd reads as topping out on its fundamental arc. Topping out — revenue and profit growth have decelerated hard (revenue growth +13.1% at its peak → +1.4% latest) while ROCE still reads 50.0%. The read is built from 9 quarters across 3 curves, on partial evidence.
Why it matters: decelerating from a peak is where good stories quietly end — the multiple usually notices late.
One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.
Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.
A partial read: at least one curve is short, or the returns curve is not the computed quarterly series — hold the stage word a little more loosely.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +10.5% | +16.0% | +30.9% | +27.0% |
| Profit | +10.4% | +54.7% | +56.0% | — |
| EPS | +10.1% | +55.2% | +55.6% | +79.2% |
| Share price | −33.3% | −13.3% | +38.7% | +39.1% |
4-Factor Sector Score
46.1/100 — rank 19 of 20 in Chemicals - Organic · 50% evidence confidence · provisional, ranked below fully-evidenced peers
Jyoti Resins and Adhesives Ltd scores 46.1 out of 100 against the 20 companies it is compared with in Chemicals - Organic, ranking 19. Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
The four contributions add to the total exactly: 13.2 + 18.7 + 10.8 + 3.4 = 46.1. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Jyoti Resins and Adhesives Ltd reported ₹72.0 Cr of revenue in the Dec 25 quarter, +1.4% year on year. That is the 8th straight quarter of year-on-year growth. Over 10 years it has compounded at 27.0% a year. The last full year, FY25, came in at ₹284 Cr. The last four reported quarters add to ₹300 Cr.
FY25 revenue came in at ₹284 Cr (+10.5% on the year), capping 10 years at 27.0% compound. The latest quarter (Dec 25) printed ₹72.0 Cr, +1.4% year on year — the 8th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +8.8% growth against the decade's 27.0% — the current year is running slower than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +8.7% over the last 4 quarters against +9.3%/yr over the last 8 — stabilising; TTM profit −5.5% vs +3.8%/yr — rolling over.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Jyoti Resins and Adhesives Ltd's operating margin is 26.0% in the Dec 25 quarter, −6.0 percentage points against the same quarter a year ago. Across 12 fiscal years the operating margin has ranged 3.0% to 33.0%. The current quarter sits inside that band.
The latest quarter's operating margin is 26.0%, −6.0 pp against the same quarter a year ago. Across 12 fiscal years the operating margin has ranged 3.0%–33.0%.
🚨 Why the margin moved: operating margin went −5.5 pp year on year while gross margin went +2.5 pp — the loss came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Jyoti Resins and Adhesives Ltd earned ₹15.0 Cr of net profit in the Dec 25 quarter, −21.1% year on year. Full-year FY25 profit was ₹74.0 Cr. That is 20.8% of the quarter's revenue. The same quarter a year earlier earned ₹19.0 Cr.
Dec 25 profit was ₹15.0 Cr, −21.1% year on year. On the full year, FY25 printed ₹74.0 Cr (+10.4%).
🚨 Why profit moved: revenue contributed +1.4% and the margin −6.0 pp — the quarter was revenue-led despite a thinner margin.
Pace comparison, last four quarters: profit −5.0% vs revenue +8.8%. Profit is growing slower than sales — costs are eating the growth before it reaches the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 23% of Jyoti Resins and Adhesives Ltd's reported profit arrived as operating cash — a gap worth watching. In FY25 that was ₹15.0 Cr of operating cash against ₹74.0 Cr of profit. After ₹2.0 Cr of capital spending, ₹13.0 Cr was left as free cash.
FY25: operating cash of ₹15.0 Cr against reported profit of ₹74.0 Cr, leaving free cash of ₹13.0 Cr after ₹2.0 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 23% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
🚨 Why conversion sits at 23%: the cash cycle tightened 191 days between FY20 and FY25 — cash that used to wait in the cycle now reaches the bank sooner. Less than 70% of profit arriving as cash is the thing to watch on this page.
Router verdict: no single sink dominates — the next section checks both the working-capital cycle and the capital spending.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Jyoti Resins and Adhesives Ltd's cash conversion cycle runs 122 days in FY25, down from 313 days in FY20. Capital spending ran ₹6.0 Cr over the last 3 years. At FY25 sales of ₹284 Cr each day of that cycle holds about ₹0.8 Cr, so roughly ₹95.0 Cr sits inside the business at any moment.
FY25: debtors at 161 days, inventory at 34 days — roughly 1.1 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 122 days, tighter than FY20's 313.
The full loop: cash goes out to suppliers and production on day 0; stock waits 34 days to sell; customers pay about 161 days after that; and suppliers themselves are paid at 72 days — netting out to the 122-day cycle.
In money terms: at FY25 sales of ₹284 Cr, each day of the cycle holds about ₹0.8 Cr — so the 122-day loop keeps roughly ₹95.0 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹6.0 Cr over the last 3 fiscal years against ₹4.0 Cr of depreciation — building somewhat ahead of wear-and-tear. Capital work-in-progress stands at ₹0.0 Cr (FY25) — capacity paid for but not yet earning.
The synthesis: neither the cycle nor the build-out is hoarding the cash — the machine is reasonably clean.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
Jyoti Resins and Adhesives Ltd earns a ROCE of 50% in FY25. That is up from a trough of 7% in FY15. A return-on-invested-capital spread against the cost of capital is not computable from what is held here. The wiring behind it is 26.1% net margin on 0.77× asset turns.
FY25 ROCE is 50%, recovered from a FY15 trough of 7% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY25): 26.1% net margin × 0.77× asset turns × 1.61× balance-sheet leverage ≈ 32.4% on equity. Margin is doing the heavy lifting; leverage is a meaningful part of the equation.
Debt Debt-to-equity says how much of the business is funded by borrowings; interest cover says how many times operating profit pays the interest bill. Low and high, respectively, is the safe corner.
Jyoti Resins and Adhesives Ltd carries ₹0.0 Cr of borrowings against ₹229 Cr of equity in FY25, a debt-to-equity of 0.00. Over 5 years borrowings went from ₹1.0 Cr to ₹0.0 Cr. Capital spending ran ₹6.0 Cr across the last 3 of those years.
FY25: borrowings of ₹0.0 Cr against equity of ₹229 Cr — a debt-to-equity of 0.00. Over 5 years borrowings went from ₹1.0 Cr to ₹0.0 Cr while capital spending ran ₹6.0 Cr in just the last 3 — the build-out is being paid for out of cash, not debt.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
Promoters added 3.1 points of Jyoti Resins and Adhesives Ltd over 8 quarters, the biggest move on the register. That takes promoters to 53.9% of the company. Domestic institutions moved +1.0 points over the same window, to 1.0%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Promoters: +3.1 points over 8 quarters to 53.9%; Domestic institutions: +1.0 points over 8 quarters to 1.0%; Foreign institutions: −0.2 points over 8 quarters to 0.0%.
Why the register moved: promoters drove it (+3.1 points), alongside domestic institutions (+1.0 points) — steady accumulation by institutions reading the same numbers this page reads.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Jyoti Resins and Adhesives Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Nitta Gelatin India LtdKERALACHEM | 82.3/100Sector-leading setup78% evidence | 27.8/35 Revenue 11.8% · PAT 34.1% · OPM change 10 pp 83% evidence | 20.2/25 ROCE 31.3% · OPM 28% 76% evidence | 14.3/20 P/E 13.5× · PEG — 50% evidence | 20.0/20 RS sector 71.7% · RS bench 85.7% · 1Y 75.4%4 of 4 weeks ahead to 2026-06-07 100% evidence | |
| Exact sum: 27.8 + 20.2 + 14.3 + 20 = 82.3 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 2Balaji Amines LtdBALAMINES | 64.9/100Mixed-positive evidence82% evidence | LEADER | 26.7/35 Revenue 11.1% · PAT 41.6% · OPM change 10 pp 95% evidence | 13.2/25 ROCE 11% · OPM 25% 76% evidence | 6.6/20 P/E 33.9× · PEG — 50% evidence | 18.4/20 RS sector 27.9% · RS bench 45.8% · 1Y 26.9%12 of 12 weeks ahead 100% evidence |
| Exact sum: 26.7 + 13.2 + 6.6 + 18.4 = 64.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3OCCL LtdOCCLLTD | 62.1/100Mixed-positive evidence60% evidence | TURNING | 26.2/35 Revenue 40.6% · PAT 100% · OPM change 7 pp 95% evidence | 12.1/25 ROCE 12.8% · OPM 28% 76% evidence | 11.5/20 P/E 10.9× · PEG — 15% evidence | 12.3/20 RS sector — · RS bench 46.7% · 1Y —3 of 3 weeks ahead 25% evidence |
| Exact sum: 26.2 + 12.1 + 11.5 + 12.3 = 62.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4Shri Ahimsa Naturals LtdSHRIAHIMSA | 60.8/100Thin evidence · provisional56% evidence | LEADER | 18.9/35 Revenue — · PAT — · OPM change -2 pp 26% evidence | 17.8/25 ROCE 21.7% · OPM 28% 95% evidence | 10.3/20 P/E 30.9× · PEG — 15% evidence | 13.8/20 RS sector 22.1% · RS bench 40.5% · 1Y 114.9%12 of 12 weeks ahead 100% evidence |
| Exact sum: 18.9 + 17.8 + 10.3 + 13.8 = 60.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 5Indo Amines LtdINDOAMIN | 59.8/100Mixed-positive evidence77% evidence | TURNING | 22.5/35 Revenue 7.6% · PAT 42.9% · OPM change 2 pp 83% evidence | 16.0/25 ROCE 19.9% · OPM 11% 95% evidence | 13.9/20 P/E 11.7× · PEG — 50% evidence | 7.4/20 RS sector -12.9% · RS bench 0.5% · 1Y -15%10 of 10 weeks ahead 70% evidence |
| Exact sum: 22.5 + 16 + 13.9 + 7.4 = 59.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Foseco India LtdFOSECOIND | 57.4/100Mixed-positive evidence83% evidence | TURNING | 18.6/35 Revenue 26.9% · PAT 7.5% · OPM change 2 pp 88% evidence | 14.9/25 ROCE 17.4% · OPM 20% 100% evidence | 11.1/20 P/E 39.7× · PEG 1.31 65% evidence | 12.8/20 RS sector 22.8% · RS bench -2.4% · 1Y 5.3%4 of 10 weeks ahead 70% evidence |
| Exact sum: 18.6 + 14.9 + 11.1 + 12.8 = 57.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 7Elantas Beck India LtdELANTAS | 50.5/100Mixed-positive evidence72% evidence | ASLEEP | 17.2/35 Revenue 11.1% · PAT 6.6% · OPM change 0 pp 83% evidence | 17.9/25 ROCE 21.2% · OPM 20% 76% evidence | 7.5/20 P/E 50.9× · PEG — 50% evidence | 7.9/20 RS sector -7.6% · RS bench -2.3% · 1Y -26%1 of 7 weeks ahead 70% evidence |
| Exact sum: 17.2 + 17.9 + 7.5 + 7.9 = 50.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8Laxmi Organic Industries LtdLXCHEM | 48.2/100Mixed-negative evidence94% evidence | TURNING | 20.8/35 Revenue 5.5% · PAT 26% · OPM change 7.6 pp 100% evidence | 8.2/25 ROCE 4.7% · OPM 12% 100% evidence | 11.8/20 P/E 39.4× · PEG 1.14 100% evidence | 7.4/20 RS sector -20.5% · RS bench 6.3% · 1Y -13.2%10 of 10 weeks ahead 70% evidence |
| Exact sum: 20.8 + 8.2 + 11.8 + 7.4 = 48.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 9Valiant Organics LtdVALIANTORG | 46.9/100Mixed-negative evidence83% evidence | ASLEEP | 23.0/35 Revenue 2.6% · PAT 100% · OPM change 2 pp 83% evidence | 9.6/25 ROCE 5.5% · OPM 12% 95% evidence | 11.4/20 P/E 25.7× · PEG — 50% evidence | 2.9/20 RS sector -18.7% · RS bench -6.3% · 1Y -29.3%7 of 12 weeks ahead 100% evidence |
| Exact sum: 23 + 9.6 + 11.4 + 2.9 = 46.9 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -18.7% and the one-year return is -29.3%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 10Shree Ganesh Remedies LtdSGRL | 46.6/100Thin evidence · provisional57% evidence | 11.3/35 Revenue -17.3% · PAT -37.7% · OPM change -4.8 pp 53% evidence | 16.4/25 ROCE 19.2% · OPM 31.9% 57% evidence | 8.9/20 P/E 35.1× · PEG — 50% evidence | 10.0/20 RS sector 2.3% · RS bench -9.9% · 1Y -15.8%4 of 12 weeks ahead to 2026-03-08 70% evidence | |
| Exact sum: 11.3 + 16.4 + 8.9 + 10 = 46.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 11Fairchem Organics LtdFAIRCHEMOR | 44.4/100Mixed-negative evidence87% evidence | BREAKING OUT | 18.4/35 Revenue 0% · PAT 50% · OPM change 6 pp 95% evidence | 5.7/25 ROCE 3.3% · OPM 10% 95% evidence | 6.0/20 P/E 66.4× · PEG — 50% evidence | 14.3/20 RS sector 1.2% · RS bench 16.6% · 1Y -12.6%8 of 12 weeks ahead 100% evidence |
| Exact sum: 18.4 + 5.7 + 6 + 14.3 = 44.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 12Fine Organic Industries LtdFINEORG | 43.3/100Mixed-negative evidence96% evidence | FADING | 13.8/35 Revenue 4.2% · PAT 1.7% · OPM change 1 pp 88% evidence | 18.0/25 ROCE 21.5% · OPM 21% 100% evidence | 6.0/20 P/E 36.2× · PEG 2.7 100% evidence | 5.5/20 RS sector -10.6% · RS bench 3.4% · 1Y -7.3%7 of 12 weeks ahead 100% evidence |
| Exact sum: 13.8 + 18 + 6 + 5.5 = 43.3 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 13GFL LtdGFLLIMITED | 43.0/100Mixed-negative evidence62% evidence | 20.6/35 Revenue 0% · PAT 100% · OPM change 2562 pp 62% evidence | 6.3/25 ROCE 2.1% · OPM 19% 95% evidence | 11.3/20 P/E 11× · PEG — 15% evidence | 4.8/20 RS sector -14.7% · RS bench -16.8% · 1Y -28.6%1 of 8 weeks ahead 70% evidence | |
| Exact sum: 20.6 + 6.3 + 11.3 + 4.8 = 43 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 14BASF India LtdBASF | 40.7/100Mixed-negative evidence90% evidence | ASLEEP | 11.9/35 Revenue -0.4% · PAT -12.5% · OPM change 1.7 pp 88% evidence | 9.3/25 ROCE 14.5% · OPM 3.2% 100% evidence | 12.2/20 P/E 38.1× · PEG 1.62 100% evidence | 7.3/20 RS sector -4.4% · RS bench -8.7% · 1Y -28%1 of 11 weeks ahead 70% evidence |
| Exact sum: 11.9 + 9.3 + 12.2 + 7.3 = 40.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 15Oriental Aromatics LtdOAL | 38.5/100Mixed-negative evidence74% evidence | TURNING | 13.0/35 Revenue 13.5% · PAT -77.7% · OPM change -0.4 pp 95% evidence | 7.2/25 ROCE 4.5% · OPM 7.6% 95% evidence | 8.7/20 P/E 231× · PEG — 15% evidence | 9.6/20 RS sector -9.8% · RS bench 15.9% · 1Y -3.1%9 of 10 weeks ahead 70% evidence |
| Exact sum: 13 + 7.2 + 8.7 + 9.6 = 38.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 16Gem Aromatics LtdGEMAROMA | 31.4/100Thin evidence · provisional56% evidence | TURNING | 4.3/35 Revenue -27.3% · PAT -80% · OPM change -8.4 pp 83% evidence | 8.6/25 ROCE 3.4% · OPM 14.2% 95% evidence | 8.5/20 P/E 705× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —2 of 10 weeks ahead 0% evidence |
| Exact sum: 4.3 + 8.6 + 8.5 + 10 = 31.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 17Sigachi Industries LtdSIGACHI | 25.4/100Adverse evidence77% evidence | TURNING | 6.2/35 Revenue -2.1% · PAT -80% · OPM change -8.8 pp 83% evidence | 6.9/25 ROCE 6.2% · OPM 13.5% 95% evidence | 8.5/20 P/E 30.4× · PEG — 50% evidence | 3.8/20 RS sector -35.5% · RS bench -8.5% · 1Y -33.6%7 of 10 weeks ahead 70% evidence |
| Exact sum: 6.2 + 6.9 + 8.5 + 3.8 = 25.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 18Sacheerome LtdSACHEEROME | 59.9/100Thin evidence · provisional41% evidence | TURNING | 17.4/35 Revenue — · PAT — · OPM change 1 pp 26% evidence | 20.6/25 ROCE 35.7% · OPM 23% 95% evidence | 10.2/20 P/E 33.3× · PEG — 15% evidence | 11.7/20 RS sector — · RS bench 30.9% · 1Y 141.7%3 of 10 weeks ahead 25% evidence |
| Exact sum: 17.4 + 20.6 + 10.2 + 11.7 = 59.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 19Jyoti Resins and Adhesives Ltdthis pageJYOTIRES | 46.1/100Thin evidence · provisional50% evidence | 13.2/35 Revenue 8.7% · PAT -5.5% · OPM change -6 pp 53% evidence | 18.7/25 ROCE 50% · OPM 26% 57% evidence | 10.8/20 P/E 14.3× · PEG — 15% evidence | 3.4/20 RS sector -20.6% · RS bench -30.3% · 1Y -40.3%0 of 12 weeks ahead to 2026-03-08 70% evidence | |
| Exact sum: 13.2 + 18.7 + 10.8 + 3.4 = 46.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 20Citurgia Biochemicals LtdCITURGIA | 41.1/100Thin evidence · provisional18% evidence | 14.3/35 Revenue — · PAT -30.4% · OPM change — 18% evidence | 6.8/25 ROCE -2150% · OPM — 46% evidence | 10.0/20 P/E — · PEG — 0% evidence | 10.0/20 RS sector — · RS bench — · 1Y — 0% evidence | |
| Exact sum: 14.3 + 6.8 + 10 + 10 = 41.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Jyoti Resins and Adhesives Ltd's share price today?
Jyoti Resins and Adhesives Ltd trades at ₹831, −33.3% over the past year. The company is valued at ₹997 Cr. The stock sits at 0% of its 52-week range of ₹831–₹1,453, −28.4% versus its 200-day average. On the tape, the price is in a downtrend, 24 weeks in. — as of 31 July 2026.
What were Jyoti Resins and Adhesives Ltd's latest quarterly results?
Jyoti Resins and Adhesives Ltd reported revenue of ₹72.0 Cr and net profit of ₹15.0 Cr for the Dec 25 quarter. Revenue rose 1.4% and profit fell 21.1% year on year. Earnings per share were ₹12.81. The operating margin was 26.0%, 6.0 pp lower than a year earlier. — as of 31 July 2026.
What is Jyoti Resins and Adhesives Ltd's revenue?
Jyoti Resins and Adhesives Ltd reported revenue of ₹72.0 Cr in the Dec 25 quarter, +1.4% year on year. For the full FY25 fiscal year, revenue was ₹284 Cr (+10.5%). Over the last 10 years revenue compounded at 27.0% a year. — as of 31 July 2026.
What is Jyoti Resins and Adhesives Ltd's profit?
Jyoti Resins and Adhesives Ltd earned ₹15.0 Cr of net profit in the Dec 25 quarter, −21.1% year on year. Full-year FY25 profit was ₹74.0 Cr. The operating margin ran 26.0% in the latest quarter. — as of 31 July 2026.
What is Jyoti Resins and Adhesives Ltd's market cap?
Jyoti Resins and Adhesives Ltd's market capitalisation is ₹997 Cr at a share price of ₹831. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 31 July 2026.
What is Jyoti Resins and Adhesives Ltd's P/E ratio?
Jyoti Resins and Adhesives Ltd trades at a P/E of 14.3×, at the 14th percentile of its own 10-year range, against a long-run median of 24.9×. This is a comparison with the stock's own history, not a value call — as of 31 July 2026.
Does Jyoti Resins and Adhesives Ltd pay a dividend?
Yes — Jyoti Resins and Adhesives Ltd's dividend payout was 15% of profit in FY25, and it recorded a payout in 6 of its last 12 reported fiscal years. This page holds the payout ratio, not a per-share amount. — as of 31 July 2026.
Is Jyoti Resins and Adhesives Ltd overvalued?
On its own history, Jyoti Resins and Adhesives Ltd looks cheap against its own history: its P/E of 14.3× has been cheaper only 14% of the time in 10 years (long-run median 24.9×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 31 July 2026.
Is Jyoti Resins and Adhesives Ltd growing?
Not right now — Jyoti Resins and Adhesives Ltd's latest numbers are shrinking: latest-quarter revenue +1.4% year on year, profit −21.1%, and the margin −6.0 pp at 26.0%. The earnings engine currently reads: deteriorating — as of 31 July 2026.
How is Jyoti Resins and Adhesives Ltd performing?
Jyoti Resins and Adhesives Ltd is in a downtrend, 24 weeks in. Its latest quarter's revenue rose 1.4% and profit fell 21.1% year on year. Against the NIFTY 500 it has been behind on a trailing-13-week view for 30 weeks. This describes what the data did, not a rating. — as of 31 July 2026.
What stage is Jyoti Resins and Adhesives Ltd in?
Topping out — revenue and profit growth have decelerated hard (revenue growth +13.1% at its peak → +1.4% latest) while ROCE still reads 50.0%. The read comes from the last 12 quarters of growth (revenue growth +1.4% latest, profit growth −21.1% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 31 July 2026.
Is Jyoti Resins and Adhesives Ltd in an uptrend?
No — the price is in a downtrend (week 24 of stage 4), trading −28.4% versus its 200-day average and at 0% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 31 July 2026.
Is Jyoti Resins and Adhesives Ltd beating the market?
Not lately — on a trailing-13-week view Jyoti Resins and Adhesives Ltd is currently behind the NIFTY 500 (30 weeks and counting; last ahead the week of 2025-08-08), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.0 years the stock moved +2,603% against the NIFTY 500's +260% — ahead of the index over the full window. — as of 31 July 2026.
Will Jyoti Resins and Adhesives Ltd's share price go up?
This page publishes no price forecast for Jyoti Resins and Adhesives Ltd. What it measures instead: the share price is ₹831, the price is in a downtrend 24 weeks in. Its P/E of 14.3× sits at the 14th percentile of its own 10-year range. — as of 31 July 2026.
Who owns Jyoti Resins and Adhesives Ltd?
Promoters hold 53.9% of Jyoti Resins and Adhesives Ltd, foreign institutions 0.0%, domestic institutions 1.0% and the public 45.0% (latest quarter). The biggest move on the register over the last two years: Promoters added 3.1 points over 8 quarters. — as of 31 July 2026.
Does Jyoti Resins and Adhesives Ltd have too much debt?
No — Jyoti Resins and Adhesives Ltd's debt-to-equity is 0.00, and operating profit covers the interest bill 1×. FY25 borrowings were ₹0.0 Cr against equity of ₹229 Cr. The returns on this page are earned, not borrowed — as of 31 July 2026.
What is Jyoti Resins and Adhesives Ltd's capex?
Jyoti Resins and Adhesives Ltd spent ₹6.0 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY25 alone that was ₹2.0 Cr, with ₹0.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 31 July 2026.
What is Jyoti Resins and Adhesives Ltd's cash flow?
Jyoti Resins and Adhesives Ltd generated ₹15.0 Cr of operating cash flow in FY25 and ₹13.0 Cr of free cash flow after ₹2.0 Cr of capital spending. Reported profit that year was ₹74.0 Cr, so operating cash ran behind profit. Cash-flow resolution for India is annual. — as of 31 July 2026.
Is Jyoti Resins and Adhesives Ltd's profit real cash?
Not fully — over the last 3 fiscal years, 23% of Jyoti Resins and Adhesives Ltd's reported profit arrived as operating cash. In FY25, operating cash was ₹15.0 Cr against reported profit of ₹74.0 Cr. The cash then goes into a mix of the working-capital cycle and capacity. Cash-flow resolution is annual — as of 31 July 2026.
Where is Jyoti Resins and Adhesives Ltd in its business cycle?
Jyoti Resins and Adhesives Ltd's FY25 operating margin was 32.0%, against a 12-year band of 3.0%–33.0%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 26.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 31 July 2026.
What could break the Jyoti Resins and Adhesives Ltd story?
The sharpest disagreement: annual EPS moved +10.1% against a −33.3% price move — the market has not yet caught up with the delivery. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 31 July 2026.
Is Jyoti Resins and Adhesives Ltd a stock worth studying right now?
This is not investment advice. The machine read: Jyoti Resins and Adhesives Ltd is cheap for a reason. The P/E sits at the 14th percentile of its own range, and the quarters are still getting worse. The sharpest open question: whether the price catches up with earnings that have already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 31 July 2026.